The Zhitong Finance App learned that Scribe Therapeutics, a biotech company dedicated to developing CRISPR gene therapy for high cholesterol and currently in phase I clinical phase, announced initial public offering (IPO) terms on Monday. The company plans to raise $100 million by issuing 7.2 million shares at a price of 13 to 15 US dollars each. The company plans to list on NASDAQ under the ticker symbol “SCTX.”

The Zhitong Finance App learned that Scribe Therapeutics, a biotech company dedicated to developing CRISPR gene therapy for high cholesterol and currently in phase I clinical phase, announced initial public offering (IPO) terms on Monday. The company plans to raise $100 million by issuing 7.2 million shares at a price of 13 to 15 US dollars each. The company plans to list on NASDAQ under the ticker symbol “SCTX.”